Differential eligibility may contribute to underrepresentation of some minoritized racial and ethnic groups in early AD trials. Amyloid biomarker eligibility is a requirement to confirm the diagnosis of AD and for treatment with amyloid-lowering drugs and differed among racial and ethnic groups.
SC Schaeffer Center researchers have turned to real-world data to probe the relationship between antihypertensive use and dementia risk in the U.S. population and among minoritized populations who are at the highest risk of dementia.
MRI and CSF biomarkers, while important for understanding dementia pathology in clinical research, were not found to substantially improve cognitive status classification based on cognitive status performance.
Providing primary care clinicians with suitable assessment tools, integrating brief cognitive assessments into routine workflows, and crafting payment policies to encourage adoption of assessments would all help improve detection.